NEW YORK, May 30, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (NASDAQ:TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that Howard L. Weiner, M.D., Chairman of Tiziana's Scientific Advisory Board and co-director of the Ann Romney Center for Neurologic Diseases at Brigham and Women's Hospital, a founding member of Mass General Brigham healthcare system, is being honored with the prestigio ...

PART I [Item 3: Key Information](index=9&type=section&id=Item%203%20Key%20Information) Selected consolidated financial data for the past five years highlights net losses, decreased assets, and significant operational and financial risks Financial Highlights (in thousands) | Financial Metric | 2023 (Thousands USD) | 2022 (Thousands USD) | 2021 (Thousands USD) | | :--- | :--- | :--- | :--- | | **Operations Data** | | | | | Research and development | $(8,113) | $(12,955) | $(13,208) | | General and administrative | $(9,871) | $(1,631) | $(13,311) | | Net loss attributable to ordinary shareholders | $(17,691) | $(15,397) | $(23,417) | | Basic and diluted net loss per ordinary share | $(0.15) | $(0.15) | $(0.24) | | **Balance Sheet Data (End of Period)** | | | | | Cash and cash equivalents | $1,183 | $18,122 | $42,186 | | Total assets | $12,184 | $26,477 | $48,826 | | Total shareholders' equity | $5,534 | $19,571 | $41,280 | [Risk Factors](index=11&type=section&id=D.%20Risk%20Factors) The company faces substantial risks including clinical trial failures, funding needs, reliance on third parties, commercialization challenges, and regulatory complexities - The company has incurred significant net losses since its inception in 2013, with a net loss of **$17.8 million** in 2023 and an accumulated loss of **$134 million** as of December 31, 2023, anticipating continued losses for the foreseeable future[56](index=56&type=chunk) - Substantial additional funding is required to complete product development, as failure to obtain this capital may force delays, limitations, or termination of development and commercialization efforts[61](index=61&type=chunk)[65](index=65&type=chunk) - The company relies heavily on licenses from Nerviano, Lonza, and Novimmune for its product candidates, and failure to comply with license obligations could result in the loss of essential rights[105](index=105&type=chunk)[111](index=111&type=chunk) - As a foreign private issuer (FPI), the company is exempt from certain SEC disclosure and corporate governance rules applicable to U.S. companies, potentially resulting in less publicly available information and different shareholder protections[238](index=238&type=chunk)[240](index=240&type=chunk) [Item 4: Information on the Company](index=70&type=section&id=Item%204%20Information%20on%20the%20Company) Tiziana Life Sciences is a clinical-stage biotechnology company developing therapies for neurodegenerative and lung diseases, with a focus on its product pipeline [History and Development of the Company](index=70&type=section&id=A.%20History%20and%20Development%20of%20the%20Company) The company reorganized its corporate structure in October 2021, establishing Tiziana Life Sciences Ltd as the ultimate Bermuda-incorporated parent - The company reorganized its corporate structure in October 2021, making Tiziana Life Sciences Ltd, a Bermuda-incorporated company, the ultimate parent of the Tiziana Group[268](index=268&type=chunk) [Business Overview](index=72&type=section&id=B.%20Business%20Overview) Tiziana focuses on developing intranasally-administered Foralumab for neurodegenerative diseases, utilizing a lean R&D model and strong IP - The company's near-term strategic focus is on the clinical development of intranasally-administered Foralumab for treating neurodegenerative diseases, particularly Secondary Progressive Multiple Sclerosis (SPMS), with other development programs temporarily paused[308](index=308&type=chunk)[295](index=295&type=chunk) Product Pipeline Overview | Product Candidate | Target Indication | Development Stage | | :--- | :--- | :--- | | **Foralumab (TZLS-401)** | Secondary Progressive MS (SPMS) | Phase 2a initiated Q3 2023 | | | Alzheimer's Disease | IND cleared Aug 2023 | | | Crohn's Disease (Oral) | Phase 1b withdrawn to focus on SPMS | | **Milciclib (TZLS-201)** | KRAS-mutated NSCLC | Program temporarily paused | | **TZLS-501 (Anti-IL6R)** | Systemic Sclerosis (SSc-ILD) | Program temporarily paused | - In an Expanded Access Program, **5 out of 6** non-active SPMS patients treated with intranasal foralumab showed a reduction in microglial activation as measured by PET scans, with the first patient showing a **38%** reduction at 6 months[360](index=360&type=chunk)[285](index=285&type=chunk)[286](index=286&type=chunk) [Item 5: Operating and Financial Review and Prospects](index=121&type=section&id=Item%205%20Operating%20and%20Financial%20Review%20and%20Prospects) Detailed analysis of financial performance reveals a net loss, decreased R&D expenses, increased G&A, and a going concern uncertainty - The independent auditor's report raises **substantial doubt** about the Group's ability to continue as a going concern, as management's forecast indicates current cash reserves will be depleted by **July 2024** without new financing[826](index=826&type=chunk)[856](index=856&type=chunk)[857](index=857&type=chunk) Operating Expenses and Loss for the Year (in thousands) | Metric (Thousands USD) | 2023 (Thousands USD) | 2022 (Thousands USD) | Change (Thousands USD) | | :--- | :--- | :--- | :--- | | Research and Development | $(8,113) | $(12,955) | $4,842 | | Operating expenses | $(9,871) | $(1,638) | $(8,233) | | **Loss for the year** | **$(17,691)** | **$(15,404)** | **$(2,287)** | - R&D expenses decreased by **$4.8 million** in 2023 compared to 2022, reflecting focused expenditure on the foralumab Phase 2 trial for SPMS and the absence of manufacturing costs for TZLS-501[585](index=585&type=chunk) - General and administrative expenses increased by **$8.2 million** in 2023, driven by higher option-related expenses, increased PR/IR costs, and a **$4.7 million** net loss from unfavorable foreign exchange movements[586](index=586&type=chunk) Cash Flow Summary (in thousands) | Cash Flow (Thousands USD) | 2023 (Thousands USD) | 2022 (Thousands USD) | | :--- | :--- | :--- | | Net cash used in operating activities | $(15,698) | $(19,615) | | Net cash used in investing activities | $(1,253) | $(3,996) | | Net cash provided by (used in) financing activities | $40 | $(55) | | **Net decrease in cash** | **$(16,911)** | **$(23,666)** | [Item 6: Directors, Senior Management and Employees](index=143&type=section&id=Item%206%20Directors,%20Senior%20Management%20and%20Employees) This section details the company's leadership, compensation, board practices, and employee count Director Compensation (2023) | Name | Position | 2023 Total Compensation (Thousands USD) | | :--- | :--- | :--- | | Gabriele Cerrone | Executive Chairman | 817 | | Willy Simon | Non-Executive Director | 89 | | John Brancaccio | Non-Executive Director | 89 | - Executive Chairman Gabriele Cerrone has a long-term realization bonus agreement entitling him to **6.5%** of the enterprise value if the company is sold for **$1 billion** or more during his directorship or within 10 years thereafter[635](index=635&type=chunk) - As of December 31, 2023, the company had **9 full-time employees**, with **3 in R&D** and **6 in management, administration, and finance**[713](index=713&type=chunk) [Item 7: Major Shareholders and Related Party Transactions](index=163&type=section&id=Item%207%20Major%20Shareholders%20and%20Related%20Party%20Transactions) Discloses ownership structure, with Executive Chairman Gabriele Cerrone holding significant influence, and outlines related party dealings - As of March 31, 2024, Executive Chairman Gabriele Cerrone beneficially owned approximately **38.71%** of the company's ordinary shares, indicating significant influence over shareholder matters[718](index=718&type=chunk)[254](index=254&type=chunk) - The company has engaged in transactions with related parties, including a shared services agreement with OKYO Pharma Ltd and a loan facility later converted into an equity investment in OKYO Pharma Ltd[978](index=978&type=chunk)[979](index=979&type=chunk) [Item 10: Additional Information](index=165&type=section&id=Item%2010%20Additional%20Information) Supplementary details cover material contracts, Bermuda exchange controls, and U.S. federal and Bermuda tax considerations for shareholders - The company believes it was a **Passive Foreign Investment Company (PFIC)** for the 2023 tax year, which could have adverse U.S. federal income tax consequences for U.S. shareholders, and the company does not intend to provide the information necessary for a QEF election[259](index=259&type=chunk)[260](index=260&type=chunk) - As a Bermuda exempted company listed on Nasdaq, Tiziana has general permission from the Bermuda Monetary Authority for the issuance and transfer of its securities to non-residents for exchange control purposes[736](index=736&type=chunk) [Item 11: Quantitative and Qualitative Disclosures About Market Risk](index=172&type=section&id=Item%2011%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) The company's primary market risks are limited to interest rate and foreign currency exchange fluctuations, without hedging activities - The company's main market risks are interest rate and foreign currency exchange fluctuations, primarily between the U.S. dollar and Pound Sterling[775](index=775&type=chunk)[965](index=965&type=chunk) - The company does not currently use currency hedging instruments to manage its foreign currency exposure[779](index=779&type=chunk) PART II [Item 15: Controls and Procedures](index=173&type=section&id=Item%2015%20Controls%20and%20Procedures) Management concluded disclosure controls were ineffective due to a material weakness in internal control over financial reporting related to an employee handbook - Management concluded that as of December 31, 2023, the company's disclosure controls and procedures were **not effective**[787](index=787&type=chunk) - A **material weakness** was identified in the internal control over financial reporting related to the failure to timely develop and communicate an employee handbook[793](index=793&type=chunk)[251](index=251&type=chunk) - Management's remediation plan involves developing and maintaining an Employee Handbook for employees to reference[794](index=794&type=chunk) [Item 16K: Cybersecurity](index=177&type=section&id=Item%2016K%20Cybersecurity) The Board of Directors oversees cybersecurity risks, supported by senior leadership and third-party security evaluations - The full Board of Directors retains oversight of cybersecurity, and senior leadership, along with a cybersecurity consultant, regularly briefs the Board on the company's security posture[810](index=810&type=chunk) - The company utilizes an incident response playbook and engages third-party services for security evaluations, such as penetration testing and independent audits[810](index=810&type=chunk)[811](index=811&type=chunk) PART III [Item 18: Financial Statements](index=178&type=section&id=Item%2018%20Financial%20Statements) Audited consolidated financial statements for 2021-2023 are presented, with the auditor highlighting a material uncertainty regarding going concern - The financial statements have been prepared assuming the company will continue as a going concern, but the auditor's report notes that the company's pre-revenue status and ongoing R&D expenditure raise **substantial doubt** about this ability, with cash forecast to be utilized by **July 2024** without additional financing[826](index=826&type=chunk) Consolidated Balance Sheet Highlights (in thousands) | (Thousands USD) | Dec 31, 2023 (Thousands USD) | Dec 31, 2022 (Thousands USD) | | :--- | :--- | :--- | | **Total Assets** | **$12,184** | **$26,477** | | Total Current Assets | $7,337 | $24,282 | | Total Non-Current Assets | $4,847 | $2,195 | | **Total Liabilities** | **$6,648** | **$6,906** | | Total Current Liabilities | $6,539 | $6,663 | | **Total Shareholders' Equity** | **$5,536** | **$19,571** |

Exhibit 99.1 Gabriele Cerrone, Executive Chairman, founder and interim Chief Executive Officer of Tiziana, commented, "After announcing our focus on advancing intranasal foralumab to address CNS-mediated inflammatory diseases, we have started this year with a stream of continuous, positive program-related developments. Intranasal foralumab's unique action on regulatory T-cells and its potential to treat multiple inflammatory pathology indications has been published in a major medical journal and recognized ...

[PART I](index=8&type=section&id=PART%20I) [Key Information](index=8&type=section&id=Item%203%20Key%20Information) This section presents the company's selected consolidated financial data for the past five years, showing consistent net losses and a decrease in cash and total assets in 2022, along with a comprehensive list of risk factors. [Selected Financial Data](index=8&type=section&id=A.%20Selected%20Financial%20Data) The company presents its audited consolidated financial data for the five years ended December 31, 2022, indicating a history of net losses, with a net loss of **$15.4 million** in 2022 and a significant decrease in cash and cash equivalents to **$18.1 million** from **$42.2 million** in the prior year Financial Performance (in thousands) | Financial Metric | 2022 | 2021 | 2020 | | :--- | :--- | :--- | :--- | | **Net Loss** | $(15,397) | $(23,417) | $(26,131) | | **Total Comprehensive Loss** | $(18,979) | $(27,895) | $(22,657) | | **Basic and Diluted Net Loss per Share** | $(0.15) | $(0.24) | $(0.16) | Balance Sheet Items (in thousands) | Balance Sheet Item | As of Dec 31, 2022 | As of Dec 31, 2021 | As of Dec 31, 2020 | | :--- | :--- | :--- | :--- | | **Cash and Cash Equivalents** | $18,122 | $42,186 | $65,824 | | **Working Capital** | $17,619 | $41,133 | $62,196 | | **Total Assets** | $26,477 | $48,826 | $70,656 | | **Total Shareholders' Equity** | $19,571 | $41,280 | $62,386 | [Risk Factors](index=10&type=section&id=D.%20Risk%20Factors) This section details significant risks facing the company, including potential clinical trial failures, a history of net losses, reliance on third parties, commercialization challenges, intellectual property dependence, and complex government regulations. - The company has incurred significant net losses since its inception in 2013, with losses of **$15.4 million**, **$23.4 million**, and **$26.1 million** for the years 2022, 2021, and 2020, respectively, accumulating to **$116 million** as of December 31, 2022[59](index=59&type=chunk) - The company relies heavily on licenses from Nerviano, Lonza, and Novimmune for patent rights and technology essential for developing its product candidates, with non-compliance potentially leading to loss of core product rights[108](index=108&type=chunk) - The company believes it was a Passive Foreign Investment Company (PFIC) for the 2022 tax year, which could subject U.S. shareholders to adverse federal income tax consequences, including higher tax rates on gains and dividends[259](index=259&type=chunk) - On June 14, 2022, the company received a notice from Nasdaq for non-compliance with the minimum **$1.00** bid price rule, although compliance was regained on April 21, 2023, the risk of failing to maintain listing standards persists[224](index=224&type=chunk)[226](index=226&type=chunk) [Information on the Company](index=67&type=section&id=Item%204%20Information%20on%20the%20Company) This section provides a comprehensive overview of Tiziana Life Sciences, detailing its history, corporate reorganization into a Bermuda-based entity, business strategy focused on neurodegenerative and lung diseases with intranasal Foralumab as its lead asset, product pipeline, competitive landscape, intellectual property, material license agreements, organizational structure, and physical properties. [History and Development of the Company](index=67&type=section&id=A.%20History%20and%20Development%20of%20the%20Company) Originally incorporated in England and Wales in 1998, the company became Tiziana Life Sciences plc in 2014, and underwent a corporate reorganization in October 2021, establishing Tiziana Life Sciences Ltd, a Bermuda-incorporated company, as the new ultimate parent. - The company executed a strategic reorganization, making Tiziana Life Sciences Ltd, a Bermuda-incorporated entity, the ultimate parent company, effective October 20, 2021[267](index=267&type=chunk) [Business Overview](index=69&type=section&id=B.%20Business%20Overview) Tiziana is a biotechnology company focused on developing therapies for neurodegenerative and lung diseases, utilizing novel administration routes, with its near-term strategy centered on advancing intranasal Foralumab for Secondary Progressive Multiple Sclerosis (SPMS) and other CNS indications. - The company's near-term strategic focus is on the clinical development of intranasally-administered Foralumab for neurodegenerative diseases, particularly SPMS, with plans to initiate a Phase 2 trial in Q3 2023[294](index=294&type=chunk)[311](index=311&type=chunk) - Development programs for the oncology drug candidate Milciclib and the anti-IL-6R mAb TZLS-501 have been temporarily paused to focus resources on the intranasal Foralumab program[304](index=304&type=chunk)[309](index=309&type=chunk)[311](index=311&type=chunk) - In an Expanded Access Program, an SPMS patient treated with intranasal Foralumab showed significant reduction in activated microglial cells, a key marker of neuroinflammation, after **3 and 6 months** of treatment, along with clinical improvements[282](index=282&type=chunk)[284](index=284&type=chunk)[285](index=285&type=chunk) - The company's core product candidates, Foralumab, Milciclib, and TZLS-501, are based on intellectual property in-licensed from Novimmune SA and Nerviano Medical Sciences S.r.l[273](index=273&type=chunk)[302](index=302&type=chunk)[305](index=305&type=chunk) [Organizational Structure](index=110&type=section&id=C.%20Organizational%20Structure) The company's organizational structure consists of the Bermuda-based parent, Tiziana Life Sciences Ltd, and its wholly-owned subsidiaries in England & Wales, the USA, and Italy. Company Subsidiaries | Name | Principal Activity | Country of Incorporation | | :--- | :--- | :--- | | Tiziana Life Sciences Ltd | Clinical stage biotechnology company | England & Wales | | Tiziana Pharma Limited | Clinical stage biotechnology company | England & Wales | | Tiziana Therapeutics Inc. | Clinical stage biotechnology company | USA | | Longevia Genomics S.r.l. | Biotechnology discovery company | Italy | [Operating and Financial Review and Prospects](index=111&type=section&id=Item%205%20Operating%20and%20Financial%20Review%20and%20Prospects) This section details the company's financial performance and condition, highlighting a net loss of **$15.4 million** in 2022, a decrease from **$23.4 million** in 2021 primarily due to lower general and administrative expenses, and a decrease in cash position to **$18.1 million** from **$42.2 million**, emphasizing its pre-revenue status and reliance on equity financing. [Results of Operations](index=123&type=section&id=A.%20Results%20of%20Operations) For the year ended December 31, 2022, the company reported a net loss of **$15.4 million**, compared to a net loss of **$23.4 million** in 2021, driven by a significant decrease in general and administrative expenses to **$1.6 million** from **$13.3 million**, while research and development expenses remained relatively stable at **$13.0 million**. Operating Expenses (in thousands) | (in thousands) | 2022 | 2021 | | :--- | :--- | :--- | | **Research and Development** | $(12,955) | $(13,208) | | **Operating Expenses (G&A)** | $(1,638) | $(13,311) | | **Loss from operations** | $(14,593) | $(27,374) | | **Loss for the year** | $(15,397) | $(23,417) | - General and administrative expenses decreased by **$11.7 million** in 2022, primarily due to a **$6.3 million** decrease in option-related expenses from forfeitures, a **$2.4 million** saving in labor costs from reduced headcount, and a **$1.5 million** reduction in legal costs[537](index=537&type=chunk) - No income tax credit was recognized in 2022, compared to a **$3.2 million** credit in 2021, as the company awaits the results of a review of its 2020 claim by HMRC before proceeding with a new claim[541](index=541&type=chunk) [Liquidity and Capital Resources](index=127&type=section&id=B.%20Liquidity%20and%20Capital%20Resources) As of December 31, 2022, the company had cash and cash equivalents of **$18.1 million**, down from **$42.2 million** at the end of 2021, primarily due to **$19.6 million** in net cash used in operating activities and **$4.0 million** used in investing activities, with future funding expected through equity sales. - The company's cash and cash equivalents decreased by **$24.1 million** during 2022, ending the year at **$18.1 million**[551](index=551&type=chunk)[552](index=552&type=chunk) Cash Flow Activities (in thousands) | (in thousands) | 2022 | 2021 | 2020 | | :--- | :--- | :--- | :--- | | **Net cash used in operating activities** | $(19,615) | $(21,762) | $(11,335) | | **Net cash used in investing activities** | $(3,996) | $(23) | $(123) | | **Net cash (used in) / provided by financing activities** | $(55) | $130 | $75,346 | - The company expects expenses to increase substantially as it advances its product candidates through clinical trials and seeks regulatory approvals, with future funding anticipated through equity offerings[559](index=559&type=chunk)[561](index=561&type=chunk) [Directors, Senior Management and Employees](index=130&type=section&id=Item%206%20Directors%2C%20Senior%20Management%20and%20Employees) This section provides information on the company's leadership and workforce, listing the three members of the Board of Directors and key senior management, detailing compensation for 2022 including a realization bonus structure for the Executive Chairman, describing equity incentive plans, outlining the board committee structure, and stating the company had **9** full-time employees as of year-end 2022. - As of December 31, 2022, the company had **9** full-time employees, with **3** in research and development and **6** in management, administration, and finance[666](index=666&type=chunk) - The Executive Chairman, Gabriele Cerrone, is eligible for a realization bonus of **3.5%** of the Enterprise Value if it equals or exceeds **£300 million** upon a sale or change of control, with a previous realization bonus triggered in August 2020[582](index=582&type=chunk)[583](index=583&type=chunk) - The company's board consists of three directors: Gabriele Marco Antonio Cerrone (Executive Chairman), Willy Simon (Non-Executive), and John Brancaccio (Non-Executive)[568](index=568&type=chunk) [Major Shareholders and Related Party Transactions](index=150&type=section&id=Item%207%20Major%20Shareholders%20and%20Related%20Party%20Transactions) This section details the ownership structure and related party dealings of the company, identifying Executive Chairman Gabriele Cerrone as the only major shareholder, beneficially owning approximately **38.58%** of the company's ordinary shares as of April 24, 2023, and outlining related party transactions including shared services agreements and loan facilities with OKYO Pharma Ltd and Rasna Therapeutics Inc. - As of April 24, 2023, Executive Chairman Gabriele Cerrone beneficially owned **39,806,023** ordinary shares, representing approximately **38.58%** of the company[671](index=671&type=chunk) - The company has a shared services agreement and provided a **$2 million** short-term credit facility to OKYO Pharma Ltd, a related party, in August 2022[916](index=916&type=chunk)[917](index=917&type=chunk) - Tiziana has a shared services agreement with Rasna Therapeutics Inc, a related party, and extended a **$75,000** loan to it during 2022[914](index=914&type=chunk) [Financial Information](index=151&type=section&id=Item%208%20Financial%20Information) This section refers to Item 18 for the company's consolidated financial statements and other related financial information, and states that the company is not currently a party to any material legal proceedings. - The company is not currently involved in any governmental, legal, or arbitration proceedings that are expected to have a significant effect on its financial position or profitability[679](index=679&type=chunk) [Additional Information](index=152&type=section&id=Item%2010%20Additional%20Information) This section provides supplementary information, including a reference to the company's memorandum of association and Bye-laws, details Bermuda's exchange control regulations, and a significant portion dedicated to U.S. and Bermuda tax considerations for shareholders, highlighting the company's belief that it qualifies as a Passive Foreign Investment Company (PFIC). - The company believes it was a Passive Foreign Investment Company (PFIC) for its 2017 tax year and expects to be a PFIC for the current taxable year, which can lead to adverse U.S. federal income tax consequences for U.S. Holders[695](index=695&type=chunk) - Under Bermuda law, there is no withholding tax on dividends or other distributions, and the company has received an assurance from the Minister of Finance of Bermuda protecting it from certain new taxes until March 31, 2035[718](index=718&type=chunk)[719](index=719&type=chunk) [Quantitative and Qualitative Disclosures About Market Risk](index=159&type=section&id=Item%2011%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) The company's primary market risks are interest rate fluctuations and foreign currency exchange rate fluctuations, with exposure to interest rate risk considered minimal due to a conservative investment portfolio, and foreign exchange risk primarily between the U.S. dollar and Pound Sterling, for which the company does not currently use hedging instruments. - The company's main market risks are interest rate and foreign currency exchange fluctuations[727](index=727&type=chunk) - The company does not currently engage in currency hedging activities to mitigate its foreign currency exchange risk[731](index=731&type=chunk) [PART II](index=160&type=section&id=PART%20II) [Controls and Procedures](index=160&type=section&id=Item%2015%20Controls%20and%20Procedures) Management has concluded that as of December 31, 2022, the company's disclosure controls and procedures were not effective due to a material weakness in the internal control over financial reporting related to an ineffective control environment, specifically the failure to timely develop and communicate an employee handbook, which management intends to remediate. - Management concluded that disclosure controls and procedures were not effective as of December 31, 2022[739](index=739&type=chunk) - A material weakness was identified in the internal control over financial reporting due to an ineffective control environment, specifically the lack of a timely developed employee handbook[744](index=744&type=chunk)[745](index=745&type=chunk) [Other Information](index=161&type=section&id=Item%2016%20Other%20Information) This section covers various governance and compliance topics, identifying John Brancaccio as the Audit Committee Financial Expert, disclosing accountant fees totaling **$325,000** in 2022, reporting the purchase of **1,683,544** of its own common shares during 2022, and reiterating that as a foreign private issuer, it follows certain home country (Bermuda) corporate governance practices in lieu of some Nasdaq requirements. - The Board of Directors has determined that Mr. John Brancaccio is an "audit committee financial expert"[747](index=747&type=chunk) Accountant Fees (in thousands) | (in thousands) | 2022 | 2021 | | :--- | :--- | :--- | | **Audit fees** | 297 | 292 | | **Other assurance services** | 28 | 32 | | **Total** | 325 | 324 | - During the year ended December 31, 2022, the company purchased **1,683,544** of its own common shares at an average price of **$0.78** per share[752](index=752&type=chunk) [PART III](index=164&type=section&id=PART%20III) [Financial Statements](index=164&type=section&id=Item%2018%20Financial%20Statements) This section contains the audited consolidated financial statements for Tiziana Life Sciences Ltd for the year ended December 31, 2022, prepared in accordance with IFRS, including the Consolidated Balance Sheets, Statements of Operations and Comprehensive Loss, Statements of Shareholders' Equity, and Statements of Cash Flows, along with detailed notes. Consolidated Balance Sheet (in thousands) | (In thousands) | Dec 31, 2022 | Dec 31, 2021 | | :--- | :--- | :--- | | **Total Assets** | $26,477 | $48,826 | | **Total Liabilities** | $6,906 | $7,546 | | **Total Shareholders' Equity** | $19,571 | $41,280 | Consolidated Statement of Operations and Comprehensive Loss (in thousands) | (In thousands) | Year ended Dec 31, 2022 | Year ended Dec 31, 2021 | | :--- | :--- | :--- | | **Total operating expenses** | $(14,586) | $(27,374) | | **Loss for the year** | $(15,397) | $(23,417) | | **Comprehensive loss** | $(18,979) | $(27,895) | - The company's financial commitments include potential future milestone payments for its licensed products, such as up to **$15 million** for Milciclib upon NDA equivalent in breast cancer and up to **$2 million** for Foralumab upon BLA approval[925](index=925&type=chunk)[926](index=926&type=chunk) [Exhibits](index=164&type=section&id=Item%2019%20Exhibits) This section lists all the exhibits filed as part of the Form 20-F annual report, including the company's memorandum of association and bye-laws, material contracts such as license agreements with Nerviano and Novimmune, lease agreements, equity incentive plans, and various certifications required by the Sarbanes-Oxley Act. - Key exhibits filed include the license agreement for Milciclib with Nerviano Medical Services S.r.l. and license agreements for Foralumab (CD3) and TZLS-501 (IL-6r) with Novimmune SA[763](index=763&type=chunk)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITI ...

[Report of Foreign Private Issuer (Form 6-K)](index=1&type=section&id=Report%20of%20Foreign%20Private%20Issuer%20%28Form%206-K%29) [Filing Information](index=1&type=section&id=Filing%20Information) This section details the filing specifics of Form 6-K by Tiziana Life Sciences plc, a foreign private issuer, on June 30, 2021 - Company: **Tiziana Life Sciences plc**[1](index=1&type=chunk) - Filing Date: **June 30, 2021**[9](index=9&type=chunk) - Report Type: **Form 6-K, Report of Foreign Private Issuer**[1](index=1&type=chunk) [Information Contained in this Report on Form 6-K](index=2&type=section&id=Information%20Contained%20in%20this%20Report%20on%20Form%206-K) This section outlines key information in the Form 6-K, including a UK RNS announcement on an interview and AGM results - On **June 30, 2021**, the company issued a regulatory news service (RNS) announcement in the United Kingdom[4](index=4&type=chunk) - The announcement covers an interview with Dr Howard Weiner on Bloomberg Markets and the Annual General Meeting results[4](index=4&type=chunk) - The RNS Announcement is furnished as **Exhibit 99.1** and is not deemed "filed" under Section 18 of the Securities Exchange Act of 1934[5](index=5&type=chunk) [Exhibit Index](index=4&type=section&id=Exhibit%20Index) This section lists the exhibit included with the Form 6-K filing List of Exhibits | Exhibit No. | Description | | :--- | :--- | | 99.1 | Regulatory News Service Announcement, dated June 30, 2021 |

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITI ...

/ tiziana LIFE SCIENCES January 2021 Corporate Presentation www.tizianalifesciences.com NASDAQ: TLSA AIM: TILS Disclaimer And Forward Looking Statements The content of this presentation has been prepared for the purpose of providing general information about, and an overview of, the Company and its business. It is not intended to be a complete review of all matters concerning the Company and nor has it been independently verified. Whilst the presentation has been prepared in good faith and the Company has t ...

An Innovative Platform in Oral, Nasal and Inhalation for Monoclonal Antibody Administration Proprietary inhalation delivery of anti-IL-6R mAb for COVID-19 treatment Advanced clinical programs in Crohn's Disease, progressive Multiple Sclerosis, and Hepatocellular Carcinoma August 2020 Corporate Presentation https://www.tizianalifesciences.com/ NASDAQ: TLSA AIM: TILS DISCLAIMER AND FORWARD LOOKING STATEMENTS 2 The content of this presentation has been prepared for the purpose of providing general information ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITI ...